-
Upsher-Smith previews expansion of rare disease portfolio at 2024 AAN annual meeting
Upsher-Smith has broadened its offerings to include Vigadrone (vigabatrin) Tablets, 500 mg. Torpenz Tablets, a branded-generic everolimus tablet, will soon be available to prescribers and patients. -
Fresenius debuts Actemra biosimilar
Tyenne, for use in the treatment of chronic autoimmune diseases, is available in an intravenous formulation.